Avacta Group Plc Company Profile (LON:AVCT)

Analyst Ratings

Consensus Ratings for Avacta Group Plc (LON:AVCT) (?)
Ratings Breakdown: 1 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: GBX 1.60

Analysts' Ratings History for Avacta Group Plc (LON:AVCT)
Show:
DateFirmActionRatingPrice TargetActions
4/25/2016Numis Securities LtdReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/9/2015Panmure GordonReiterated RatingBuyGBX 1.75View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/24/2014 forward)

Earnings

Earnings History for Avacta Group Plc (LON:AVCT)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Avacta Group Plc (LON:AVCT)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Avacta Group Plc (LON:AVCT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Avacta Group Plc (LON:AVCT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
7/7/2016Albin,Michael ScottInsiderBuy3,393GBX 92£3,121.56Tweet This Trade  Share This Trade on StockTwits
4/29/2016Slater ,CraigInsiderBuy2,222GBX 113£2,510.86Tweet This Trade  Share This Trade on StockTwits
4/6/2016Albin,Michael ScottInsiderBuy899GBX 116£1,042.84Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Avacta Group Plc (LON:AVCT)
DateHeadline
07/14/16 02:43 PMAvacta : Collaboration with Glythera
07/14/16 02:28 AMCollaboration with Glythera - [at noodls] - Avacta and Glythera announce collaboration to develop novel, potentially highly potent, drug class · The collaboration will evaluate the use of Avacta's Affimer technology in combination with Glythera's ...
07/08/16 10:43 AMAvacta Group PLC
06/30/16 02:49 PMAvacta Rapidly Generates Affimer Binders for Zika Virus Diagnostics
06/22/16 02:59 AMAffimer Binders for Zika Virus Diagnostics - [at noodls] - Avacta Rapidly Generates · Rapid generation and validation of three distinct and highly specific Affimer binders to Zika virus within just thirteen weeks of receiving the virus target. · The Affimer reagents ...
06/13/16 10:44 AMAvacta : Collaboration with Mologic
06/13/16 02:29 AMCollaboration with Mologic - [at noodls] - RNS Number : 9394A Avacta Group PLC 13 June 2016 Avacta and Mologic Enter Research and Product Development Collaboration Agreement · Avacta's Affimer technology will be used to develop rapid lateral flow ...
04/29/16 11:50 AMDirectors dealings: John Laing Group chief picks up batch of shares -
04/25/16 06:07 AMHalf Year 2016 Avacta Group PLC Earnings Release - Before Market Open -
04/19/16 02:35 AMAffimer Therapeutic Platform Development Milestone - [at noodls] - RNS Number : 5685V Avacta Group PLC 19 April 2016 19 April 2016 Avacta Group plc ("Avacta" or "the Group") Achieved Important multi-Affimer formats can be manufactured easily and with ...
04/05/16 02:54 AMInvestor Evening - [at noodls] - RNS Number : 1344U Avacta Group PLC 05 April 2016 05 April 2016 Avacta Group plc ("Avacta" or "the Group" or "the Company") - Thursday 5 May 2016 A discussion of its proprietary ...
03/08/16 09:06 AMAvacta appoints scientific advisory board -
01/26/16 02:27 AMShare Consolidation - [at noodls] - RNS Number : 9470M Avacta Group PLC 26 January 2016 26 January 2016 Avacta Group plc ("Avacta" or "the Group" or "the Company") Avacta Group plc (AIM: AVCT), the developer ...
01/25/16 02:27 AMPhilippe Cotrel Appointed Chief Commercial Officer - [at noodls] - RNS Number : 8242M Avacta Group PLC 25 January 2016 25 January 2016 Avacta Group plc ("Avacta" or "the Group" or "the Company") Avacta Appoints Philippe Cotrel as Chief Commercial ...
01/21/16 12:49 PMAvacta Group PLC (AVCT) - Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and research reagents, is undertaking a share consolidation of 1 new ordinary share of 10p each for every 100 existing ordinary shares of 0.1p each (the "Share Consolidation").
01/21/16 02:25 AMProposed Shareholder Consolidation - [at noodls] - RNS Number : 5156M Avacta Group PLC 21 January 2016 Avacta Group plc ("Avacta" or the "Group") Proposed Share Consolidation Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics ...
01/07/16 02:18 AMPosting of Annual Report & Accounts and AGM Notice - [at noodls] - RNS Number : 0835L Avacta Group PLC 07 January 2016 7 January 2016 Avacta Group plc ("Avacta" or the "Group") Posting of Annual Report & Accounts and AGM Notice Avacta Group plc (AIM: ...
12/10/15 02:29 AMAppointment of Tony Gardiner as CFO - [at noodls] - RNS Number : 5812I Avacta Group PLC 10 December 2015 10 December 2015 Avacta Group plc ('Avacta' or 'the Group') Avacta Appoints Tony Gardiner as Chief Financial Officer Tim Sykes stepping down from role; ...
10/26/15 10:45 AMAvacta Group plc - Preliminary Results for the Year Ended 31 July 2015 - [at noodls] - 26 Oct 2015 Substantial progress in early commercialisation of Affimer® molecules as potentially superior alternatives to antibodies Significant funds raised to establish in-house Affimer therapeutics ...
10/19/15 02:31 AMAffimers improve disease resistance in plants - [at noodls] - RNS Number : 6117C Avacta Group PLC 19 October 2015 19 October 2015 Avacta Group plc ('Avacta' or 'the Group') Affimers shown to improve disease resistance in plants Research from the University of Copenhagen ...
10/09/15 03:17 AMAvacta Group plc - Robust performance of Affimers on Luminex platform - [at noodls] - 09 Oct 2015 Avacta's collaborator ProtATonce demonstrates robust performance of Affimers on Luminex platform Results presented at Biomarker Summit Europe, Berlin Avacta Group plc (AIM: AVCT), the developer ...
10/09/15 02:27 AMRobust performance of Affimers on Luminex platform - [at noodls] - RNS Number : 6520B Avacta Group PLC 09 October 2015 09 October 2015 Avacta Group plc ('Avacta' or 'the Group') Avacta's collaborator ProtATonce demonstrates robust performance of Affimers on Luminex platform ...
09/17/15 04:11 AMAvacta Group plc - Appoints Dr Mike Owen as Non-executive Director - [at noodls] - Portfolio news 2015 17 Sep 2015 Avacta Group plc (AIM: AVCT), the global provider of proprietary diagnostic tools, consumables and reagents for life sciences, is pleased to announce that it has appointed ...
09/17/15 02:31 AMAppoints Dr Mike Owen as Non-executive Director - [at noodls] - RNS Number : 3081Z Avacta Group PLC 17 September 2015 17 September 2015 Avacta Group plc ('Avacta' or 'the Group') Avacta Adds extensive biopharmaceutical development and commercialisation expertise to ...

Social

About Avacta Group Plc

Avacta Group Plc logoAvacta Group plc is a provider of research reagents, consumables and equipment to the life sciences and animal care markets. The Company provides research, development, production and delivery of instrumentation and services for the biopharmaceutical drug development and clinical diagnostics markets using biophysical technology. It operates through three segments: Analytical, Animal Health and Life Sciences. The Analytical segment provides tools and contract services for early stage protein characterisation and analysis for biopharmaceutical drug developers. The Animal Health segment provides tools and contract services to assist diagnosis of conditions in animals to enable faster treatment for veterinarians. The Life Sciences segment provides reagents and arrays for diagnostics, drug and biomarker discovery in biotech research and development. Its subsidiaries include Avacta Limited, Avacta Analytical Limited, Oriental Fine Foods Limited, Avacta Health Limited and others.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: LON
  • Symbol: AVCT
  • CUSIP:
Key Metrics:
  • Previous Close: $1.12
  • 50 Day Moving Average: $95.11
  • 200 Day Moving Average: $110.48
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $56.73M
  • Current Year EPS Consensus Estimate: $-5.37 EPS
  • Next Year EPS Consensus Estimate: $N/A EPS
Additional Links: